Annexin A10 in Human Oral Cancer: Biomarker for Tumoral Growth via G1/S Transition by Targeting MAPK Signaling Pathways

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Shimizu, Toshihiro ^a   Kasamatsu, Atsushi ^a,b   Yamamoto, Ayumi ^a   Koike, Kazuyuki ^a   Ishige, Shunsaku ^a   Takatori, Hiroaki ^a   Sakamoto, Yosuke ^b   Ogawara, Katsunori ^b   Shiiba, Masashi ^b   Tanzawa, Hideki ^a,b   Uzawa, Katsuhiro ^a,b  

^a CHIBA UNIVERSITY   (Japan)

^b CHIBA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; ANNEXIN A10; CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INACTIVATION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION;

AGED; AGED, 80 AND OVER; ANNEXINS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM STAGING; RNA INTERFERENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866460587     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045510     Document Type: Article

References (56)

1. Chang KS, Wang G, Freireich EJ, Daly M, Naylor SL, et al. (1992) Specific expression of the annexin VIII gene in acute promyelocytic leukemia. Blood 79: 1802-10.
2. Pencil SD, Toth M, (1998) Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 16: 113-21.
3. Sarkar A, Yang P, Fan YH, Mu ZM, Hauptmann R, et al. (1994) Regulation of the expression of annexin VIII in acute promyelocytic leukemia. Blood 84: 279-86.
4. Theobald J, Hanby A, Patel K, Moss SE, (1995) Annexin VI has tumour-suppressor activity in human A431 squamous epithelial carcinoma cells. Br J Cancer 71: 786-8.
5. Masaki T, Tokuda M, Ohnishi M, Watanabe S, Fujimura T, et al. (1996) Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 24: 72-81.
6. Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, et al. (1996) Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res 56: 3855-8.
7. Kataoka TR, Ito A, Asada H, Watabe K, Nishiyama K, et al. (2000) Annexin VII as a novel marker for invasive phenotype of malignant melanoma. Jpn J Cancer Res 91: 75-83.
8. Han EK, Tahir SK, Cherian SP, Collins N, Ng SC, (2000) Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. Br J Cancer 83: 83-8.
9. Liu SH, Lin CY, Peng SY, Jeng YM, Pan HW, et al. (2002) Down-regulation of annexin A10 in hepatocellular carcinoma is associated with vascular invasion, early recurrence, and poor prognosis in synergy with p53 mutation. Am J Pathol 160: 1831-7.
10. Garcia Pedrero JM, Fernandez MP, Morgan RO, Herrero Zapatero A, Gonzalez MV, et al. (2004) Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status. Am J Pathol 164: 73-9.
11. Yamano Y, Uzawa K, Shinozuka K, Fushimi K, Ishigami T, et al. (2008) Hyaluronan-mediated motility: A target in oral squamous cell carcinoma. Int J Oncol 32: 1001-1009.
12. Gerke V, Moss SE, (2002) Annexins: from structure to function. Physiol Rev 82: 331-71.
13. Gerke V, Creutz CE, Moss SE, (2005) Annexins: linking Ca2+ signalling to membrane dynamics. Nat Rev Mol Cell Biol 6: 449-61.
14. van Baal JW, Milano F, Rygiel AM, Bergman JJ, Rosmolen WD, et al. (2005) A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology 129: 1274-81.
15. Kim JK, Kim PJ, Jung KH, Noh JH, Eun JW, et al. (2010) Decreased expression of annexin A10 in gastric cancer and its overexpression in tumor cell growth suppression. Oncol Rep 24: 607-12.
16. Munksgaard PP, Mansilla F, Brems Eskildsen AS, Fristrup N, Birkenkamp-Demtröder K, et al. (2011) Low ANXA10 expression is associated with disease aggressiveness in bladder cancer. Br J Cancer 105: 1379-87 doi: 10.1038/bjc.2011.404.
17. Coolican SA, Samuel DS, Ewton DZ, McWade FJ, Florini JR, (1997) The mitogenic and myogenic actions of insulin-like growth factors utilize distinct signaling pathways. J Biol Chem 272: 6653-6662.
18. Alldridge LC, Harris HJ, Plevin R, Hannon R, Bryant CE, (1999) The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 274: 37620-8.
19. Iseki Y, Imoto A, Okazaki T, Harigae H, Takahashi S, (2009) Identification of annexin 1 as a PU.1target gene in leukemia cells. Leuk Res 33: 1658-63.
20. Meloche S, Pouysségur J, (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26: 3227-39.
21. Mebratu Y, Tesfaigzi Y, (2009) How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle 8: 1168-75.
22. Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, et al. (1995) Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-97.
23. Lavoie JN, L'Allemain G, Brunet A, Müller R, Pouysségur J, (1996) Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-16.
24. Greulich H, Erikson RL, (1998) An analysis of Mek1 signaling in cell proliferation and transformation. J Biol Chem. 273: 13280-8.
25. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, et al. (2005) Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 24: 3459-71.
26. Wey JS, Gray MJ, Fan F, Belcheva A, McCarty MF, et al. (2005) Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer 93: 233-41.
27. Mountzios G, Planchard D, Besse B, Validire P, Girard P, et al. (2008) Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. Clin Cancer Res 14: 4096-102.
28. Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, et al. (2011) PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene doi: 10.1038/onc.2011.515.
29. Mukherjee S, Poddar R, Deb I, Paul S, (2011) Dephosphorylation of specific sites in the kinase-specificity sequence domain leads to ubiquitin-mediated degradation of the tyrosine phosphatase STEP. Biochem J 440: 115-25.
30. Fearon ER, Vogelstein B, (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-67.
31. Marshall CJ, (1991) Tumor suppressor genes. Cell 64: 313-26.
32. McCubrey JA, Steelman LS, Franklin RA, Abrams SL, Chappell WH, et al. (2007) Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul 47: 64-103.
33. Cook SJ, Lockyer PJ, (2006) Recent advances in Ca(2+)-dependent Ras regulation and cell proliferation. Cell Calcium 39: 101-12.
34. Kisielewska J, Philipova R, Huang JY, Whitaker M, (2009) MAP kinase dependent cyclinE/cdk2 activity promotes DNA replication in early sea urchin embryos. Dev Biol 334: 383-94.
35. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, et al. (2002) Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 62: 3200-6.
36. Yue H, Jiang HY, (2005) Expression of cell cycle regulator p57kip2, cyclin E protein and proliferating cell nuclear antigen in human pancreatic cancer: an immunohistochemical study. World J Gastroenterol 11: 5057-60.
37. Le Gall M, Grall D, Chambard JC, Pouysségur J, Van Obberghen-Schilling E, (1998) An anchorage-dependent signal distinct from p42/44 MAP kinase activation is required for cell cycle progression. Oncogene 17: 1271-7.
38. Roovers K, Davey G, Zhu X, Bottazzi ME, Assoian RK, (1999) Alpha5beta1 integrin controls cyclin D1 expression by sustaining mitogen-activated protein kinase activity in growth factor-treated cells. Mol Biol Cell 10: 3197-204.
39. Viglietto G, Motti ML, Fusco A, (2002) Understanding p27(kip1) deregulation in cancer: down-regulation or mislocalization. Cell Cycle 1: 394-400.
40. Perisanidis C, Perisanidis B, Wrba F, Brandstetter A, El Gazzar S, et al. (2012) Evaluation of immunohistochemical expression of p53, p21, p27, cyclin D1, and Ki67 in oral and oropharyngeal squamous cell carcinoma. J Oral Pathol Med 41: 40-6 doi: 10.1111/j.1600-0714.2011.01071.x.
41. Kawada M, Yamagoe S, Murakami Y, Suzuki K, Mizuno S, et al. (1997) Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. Oncogene 15: 629-37.
42. Nah SS, Won HJ, Park HJ, Ha E, Chung JH, et al. (2009) Melatonin inhibits human fibroblast-like synoviocyte proliferation via extracellular signal-regulated protein kinase/P21(CIP1)/P27(KIP1) pathways. Park J Pineal Res 47: 70-4.
43. Lin N, Chen S, Pan W, Xu L, Hu K, et al. (2011) NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am J Physiol Cell Physiol 301: C469-77.
44. Harada M, Miyata K, Wada T, Oomata T, Morita N, et al. (1993) Establishment and characterization of a cell line(Sa3) from squamous cell carcinoma of the human gingiva. Jpn J Oral Maxillofac Surg 39: 965-971.
45. Koike H, Uzawa K, Grzesik WJ, Seki N, Endo Y, et al. (2005) GLUT1 is highly expressed in cementoblasts but not in osteoblasts. Connect Tissue Res 46: 117-24.
46. Kasamatsu A, Uzawa K, Nakashima D, Koike H, Shiiba M, et al. (2005) Galectin-9 as a regulator of cellular adhesion in human oral squamous cell carcinoma cell lines. Int J Mol Med 16: 269-273.
47. Endo Y, Uzawa K, Mochida Y, Nakatsuru M, Shiiba M, et al. (2004) Sarcoendoplasmic reticulum Ca2+ ATPase type 2 downregulated in human oral squamous cell carcinoma. Int J Cancer 110: 225-231.
48. Sakuma K, Kasamatsu A, Yamatoji M, Yamano Y, Fushimi K, et al. (2010) Expression status of Zic family member 2 as a prognostic marker for oral squamous cell carcinoma. J Cancer Res Clin Oncol 136: 553-9.
49. Yamatoji M, Kasamatsu A, Kouzu Y, Koike H, Sakamoto Y, et al. (2011) Dermatopontin: A potential predictor for metastasis of human oral cancer. Int J Cancer doi: 10.1002/ijc.26328.
50. Ferrero M, Ferragud J, Orlando L, Valero L, Sánchez del Pino M, et al. (2011) Phosphorylation of AIB1 at mitosis is regulated by CDK1/CYCLIN B. PLoS One. 6(12): e28602.
51. Díaz-Rodríguez E, Álvarez-Fernández S, Chen X, Paiva B, López-Pérez R, et al. (2011) Deficient spindle assembly checkpoint in multiple myeloma.PLoS One. 6(11): e27583.
52. Lombardi DP, Geradts J, Foley JF, Chiao C, Lamb PW, et al. (1999) Loss of KAI1 expression in the progression of colorectal cancer. Cancer Res 59: 5724-31.
53. Kouzu Y, Uzawa K, Kato M, Higo M, Nimura Y, et al. (2006) Overexpression of stathmin in oral squamous-cell carcinoma: Correlation with tumour progression and poor prognosis. Br J Cancer 94: 717-723.
54. Shimada K, Uzawa K, Kato M, Endo Y, Shiiba M, et al. (2005) Aberrant expression of RAB1A in human tongue cancer. Br J Cancer 92: 1915-1921.
55. Iyoda M, Kasamatsu A, Ishigami T, Nakashima D, Endo-Sakamoto Y, et al. (2010) Epithelial cell transforming sequence 2 in human oral cancer. PLoS One 5: e14082.
56. Verburg FA, Wäschle K, Reiners C, Giovanella L, Lentjes EG, (2010) Heterophile antibodies rarely influence the measurement of thyroglobulin and thyroglobulin antibodies in differentiated thyroid cancer patients. Horm Metab Res 42: 736-739.